Incompatible Natures of the HIV-1 Envelope in Resistance to the CCR5 Antagonist Cenicriviroc and to Neutralizing Antibodies.

about

Driving HIV-1 into a Vulnerable Corner by Taking Advantage of Viral Adaptation and Evolution.Prediction of HIV-associated neurocognitive disorder (HAND) from three genetic features of envelope gp120 glycoprotein.

P2860

Q37703084-B4263BFA-05C0-45DA-98E3-2839A113E13D Q47548593-7EAADF10-179D-4C70-9E91-C2A357021BDD

P2860

Incompatible Natures of the HIV-1 Envelope in Resistance to the CCR5 Antagonist Cenicriviroc and to Neutralizing Antibodies.

Item

http://www.wikidata.org/entity/Q38822845

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Incompatible Natures of the HI ...... nd to Neutralizing Antibodies.

@en

type

Item

label

Incompatible Natures of the HI ...... nd to Neutralizing Antibodies.

@en

prefLabel

Incompatible Natures of the HI ...... nd to Neutralizing Antibodies.

@en

P1476

Incompatible Natures of the HI ...... nd to Neutralizing Antibodies.

@en

P2093

Ikumi Enomoto

http://www.w3.org/2001/XMLSchema#string

Masanori Baba

http://www.w3.org/2001/XMLSchema#string

Shuzo Matsushita

http://www.w3.org/2001/XMLSchema#string

Takeo Kuwata

http://www.w3.org/2001/XMLSchema#string

P2860

Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1

TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans

Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system

Identification of gammaretroviruses constitutively released from cell lines used for human immunodeficiency virus research

Neutralizing antibody and anti-retroviral drug sensitivities of HIV-1 isolates resistant to small molecule CCR5 inhibitors

CCR5 antagonism in HIV infection: current concepts and future opportunities

Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120

The Conformation and Orientation of a 27-Residue CCR5 Peptide in a Ternary Complex with HIV-1 gp120 and a CD4-Mimic Peptide

Broad and potent neutralization of HIV-1 by a gp41-specific human antibody

Structure of the CCR5 Chemokine Receptor-HIV Entry Inhibitor Maraviroc Complex

P304

437-450

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.02285-15

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-11-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26525792

http://www.w3.org/2001/XMLSchema#string

P932

4704143

http://www.w3.org/2001/XMLSchema#string

Incompatible Natures of the HIV-1 Envelope in Resistance to the CCR5 Antagonist Cenicriviroc and to Neutralizing Antibodies.

about

P2860

P2860

Incompatible Natures of the HIV-1 Envelope in Resistance to the CCR5 Antagonist Cenicriviroc and to Neutralizing Antibodies.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932